Check out the latest features and columns!

Pharmaceutical Executive May 2023

Scientist-turned-entrepreneur steers efforts to transform approaches in tissue regeneration.

Rejuvenating Lives

The recipe for cross-functional collaboration in drug development.

A Knack for Problem-Solving

How the pivot to corporate development became a natural fit for once-destined scientist.

From Science to Strategy

Driving commercial growth and patient access and empowerment in women’s health.

Committed to the Cause

Chronicling one leader’s call to duty in dermatology.

Mission-Fueled Mindset

Articles

Rexulti to be first authorized treatment for agitation associated with dementia. 

Image Credit: Adobe Stock Images/New Africa

Alzheimer's Agitation Drug. Image Credit: Adobe Stock Images/New Africa

Otsuka, Lundbeck Receive FDA Approval for New Alzheimer’s Medication

Collaboration expected to drive consumer and patient engagement in the region. 

Doceree, Hello Health Group Announce Partnership In 8 Southeast Asian Markets 

, an MJH Life Sciences sister publication. 

How the pivot to corporate development became a natural fit for the once-destined scientist. (The story of Natasha A. Hernday, chief business officer of Seagen and a 2023 Emerging Pharma Leader.)

From Science to Strategy | 2023 Emerging Pharma Leader

Miranda Schmalfuhs is the associate group social media editor of 

Pharmaceutical Executive, Pharmaceutical Commerce

 and can be reached at mschmalfuhs@mjhlifesciences.com.

Driving commercial growth and patient access and empowerment in women’s health. (The story of Simon Holland, vice president, women's health commercial lead, for Organon and a 2023 Emerging Pharma Leader.)

Committed to the Cause | 2023 Emerging Pharma Leader

 and can be reached at mhollan@mjhlifesciences.com.

The recipe for cross-functional collaboration in drug development. (The story of Justin To, chief operating officer, skeletal dysplasias and gene therapy, for Bridge Bio and a 2023 Emerging Pharma Leader.)

A Knack for Problem-Solving | 2023 Emerging Pharma Leader

 and can be reached at fpollaro@mjhlifesciences.com.

Chronicling one leader’s call to duty in dermatology. (The story of Frank Watanabe, president and CEO of Arcutis Biotherapeutics and a 2023 Emerging Pharma Leader.)

Mission-Fueled Mindset | 2023 Emerging Pharma Leader

 and can be reached at mrivers@mjhlifesciences.com.

Scientist-turned-entrepreneur steers efforts to transform approaches in tissue regeneration. (The story of Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics and a 2023 Emerging Pharma Leader.)

Rejuvenating Lives | 2023 Emerging Pharma Leader

Podcasts

Torrey Cope, partner, food, drug, and medical device practice, Sidley Austin LLP, reveals current regulatory challenges in the U.S. for drug approvals, how a one-sized-fits-all approach to marketing and global launches no longer works, and when a global launch may be advantageous.  

Drug Approvals and Launches from a Legal Perspective

Government sponsored study to test effectiveness of Quviviq in those living with PTSD. 

Idorsia Pharmaceuticals Reveals Support for Department of Defense Clinical Trials 

Kyle Forcier is the senior director of life sciences and product marketing for Model N.

According to the latest State of Revenue survey of c-suite executives, pharma manufacturers are prioritizing digital transformation while struggling with inflation and supply chain disruptions.